Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
Chondrosarcoma is a rare cancer originating in the cartilage, making it an exceptional case of market forces acting upon a disease. There are several elements that contribute to Chondrosarcoma market as a whole. The threat this malignancy poses is mainly about its prevalence. In comparison to other common cancers, Chondrosarcoma being a rare kind of neoplasia afflicts relatively few people. This scarcity influences the dynamic of the market through affecting research funding, drug development and overall market size.
Market factors significantly influenced by prognosis and severity Chondrosarcoma. Because this type of cancer is slowly growing and is of various grades of aggression there may be different approaches depending on the subtype and stage (Oliveira et al 3). As such there are several therapeutic options as diverse as surgery, radiation or even emerging targeted therapies among others because of these complexities (Oliveira et al 3). There is competitive landscape within chondrosarcoma characterized by diversity in modalities for treatment thereby impacting upon adoption rates for different therapies.
The diagnostic landscape is another crucial factor in the Chondrosarcoma market. Early detection remains difficult due to vague symptoms and low awareness about this rare tumor (Goldberg et al 1). It requires advancements in diagnostic technologies and increased awareness among healthcare professionals for improving early detection rates (Goldberg et al 1). Hence this affects demand for diagnostics tools such as imaging techniques or molecular diagnostics within the market.
In the Chondrosarcoma Market, research and development (R&D) plays an extensive role. Therefore constant scientific efforts are required to understand underlying biology and identify new therapeutic targets because of its rarity as well as heterogeneity (Fukushima et al 4). Innovation in drug development can only be driven by collaborations between pharmaceutical companies, academic institutions, and research organizations (Fukushima et al 4). In turn, the presence of breakthrough treatments for chondrosarcoma largely depends on how much has been invested into its research (Fukushima et al 4).
Government regulations and healthcare policies also play a pivotal role in shaping the Chondrosarcoma market. Regulatory frameworks may influence the speed with which innovative treatments reach patients by setting rules for approval processes of new therapies (Ozerdem & Ekmekcioglu 12). Other than that, reimbursement policies do affect accessibility of these treatments thereby impacting market dynamics and adoption rates for novel therapies (Ozerdem & Ekmekcioglu 12).
Furthermore, economic aspects of Chondrosarcoma market are influenced by factors such as health care infrastructure, patient demographics, and socio-economic conditions. This affects geographical distribution of the market as well as overall growth potential thus, advanced healthcare facilities access and treatment affordability vary globally.
Patient advocacy groups and their efforts to raise awareness about this disease and support research initiatives are crucial market factors. This assists in building an encouraging atmosphere towards research and development through public education done by these groups about Chondrosarcoma to health professionals . Therefore, there is demand for better diagnostics, improved patient care including enhanced treatment options due to patient advocacy level within various communities (Luthra et al 5).
Chondrosarcoma Market Highlights:
Global Chondrosarcoma Market Overview
The Global Chondrosarcoma Market is projected to reach USD 1,321.4 Million by 2030 at 6.8% CAGR during the forecast period 2022-2030.
Chondrosarcoma is a rare type of bone cancer that consist predominantly of cartilage. It mostly affect pelvis, upper arms (humerus), thighs (femur), ribs, and shoulder blades (scapula) and is the most common in people older than 40 years.
Rising funding for R&D and clinical trials as well as FDA approvals are major driving forces for global chondrosarcoma market. Major players are funding large amount of money in new product development for effective cure that is another key driver for the market.
In August 2022, the European Commission (EC) gave orphan medicinal product designation to Inhibrx, Inc. for INBRX-109 in chondrosarcoma following a positive opinion from the European Medicines Agency (EMA). The EC grants orphan designation to drugs and biologics intended for the safe and effective treatment, prevention, or diagnosis of a disease that is life-threatening or chronically debilitating, impacting fewer than five in 10,000 patients in the European Union. Orphan drug designation in the EU can provide certain benefits, such as reduced regulatory fees, clinical protocol assistance, and up to ten years of market exclusivity upon regulatory approval. Chondrosarcoma is an orphan bone cancer that accounts for roughly 2,800 new cases each year in the U.S. and EU together. For this condition, there are no approved therapies.
In May 2023, Servier will be showcasing new data across its robust global oncology portfolio at ASCO – June 2-6th designed to bring tomorrow closer to our patients with cancer from all around the globe–. These latest data, including plenary session selection indicating Servier’s expansive oncology pipeline &portfolio as well as the company’s commitment to improving outcomes for underserved high unmet medical needs cancer types in hard-to-treat settings, have been submitted for consideration by ASCO abstract reviewers fare indicative of what we want these conditions in order get a better response from them. A breaking abstract with results from the Phase III INDIGO study of vorasidenib among patients with residual or recurrent grade II IDH-mutant glioma will also be presented at ASCO.
Study objectives of Global Chondrosarcoma Market:
- To provide detailed analysis of the global Chondrosarcoma market structure with historical and forecast revenue for the next 6 years of the various segments and sub-segments of the Chondrosarcoma market
- To provide insights about the key drivers, restraints, opportunities and challenges affecting the growth of the global Chondrosarcoma market
- To provide analysis of the market with respect to four main geographies and their countries - America, Europe, Asia-Pacific, and Middle East & Africa.
- To provide detailed analysis of the market segmented by types, diagnosis, treatment, end user and its sub-segments.
- To provide a detailed analysis of global Chondrosarcoma market mainly based on Value chain analysis, Porter’s five forces, Price analysis, and Supply Chain analysis etc.
- To provide a detailed country level analysis of the market with respect to the current market size and future prospects.
- To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global Chondrosarcoma market
- To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the Chondrosarcoma market
FIGURE 1 GLOBAL CHONDROSARCOMA MARKET SHARE BY TYPES, 2016 (%) 
Intended Audience:
- Chondrosarcoma medicine manufacturers
- Chondrosarcoma medicine and treatment providers
- Hospitals and clinics
- Medical Research laboratories
- Research and Development (R&D) Companies
- Market Research and Consulting Service Providers
- Potential Investors
Research Methodology: 
Sources: National Center for Biotechnology Information, National Kidney Foundation, Inc., CheckOrphan, Directorate of Industries, Annual report, White paper, Company Presentation
Global Chondrosarcoma Market Segmentation
Global chondrosarcoma market has been segmented on the basis of types which comprises of conventional chondrosarcoma, clear cell chondrosarcoma, myxoid chondrosarcoma, mesenchymal chondrosarcoma, de-differentiated chondrosarcoma.
On the basis of diagnosis, it is segmented into biopsy, imaging, and others. Biopsy is further sub-segmented into shave open biopsy, core needle biopsy, and others. Imaging is further sub-segmented into X-Ray, Computed Tomography Scan (CT scan), Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET) Scan, and others.
On the basis of treatment, the market has been segmented into intensive surgery, therapies, hemipelvectomy, and others. Therapies are further sub-segmented into physical therapy, radiation therapy, chemotherapy, and others. Hemipelvectomy is further sub-segmented into external hemipelvectomy, internal hemipelvectomy, and others.
On the basis of end user, it is segmented into hospitals and clinics, medical research centers, academic institutes, and others.
Regional Analysis of Global Chondrosarcoma Market
Considering the global scenario of the market, North America holds the largest market share owing to various factors such as increasing prevalence of chondrosarcoma and increasing investment in R&D. Europe is the second largest market due to advanced healthcare facilities where the countries like Germany and UK are holding the largest market share. New cases of chondrosarcoma are rising in Asia Pacific region. Additionally, improving healthcare infrastructure and rising healthcare expenditure are driving the growth for Asia Pacific chondrosarcoma market. Due to low knowledge of disease and treatment, Middle East and Africa (ME&A) is likely to have a limited growth in the market.
Key Players for Global Chondrosarcoma Market
Some of the key players in this market are:
- Abbott. (US)
- AbbVie Inc. (US)
- Akorn, Inc. (US)
- Agios, Inc. (US)
- Baxter (US)
- Bayer AG (US)
- Epizyme, Inc. (US)
- Novartis AG (Switzerland)
- Mylan N.V. (US)
The report for Global Chondrosarcoma Market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain deeper insight to the market and industry performance. The report gives a clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different market segments and regions
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
